China's Berry Genomics Runs More than 150K NIPT; Aims to Move into Single-Gene Disorders, PGS | GenomeWeb

China's Berry Genomics, a genetic test developer and next-generation sequencing service provider, has evaluated over 150,000 of its noninvasive prenatal tests for fetal aneuploidy and is aiming to develop tests for fetal single-gene disorders and preimplantation genetic screening in the short term and for oncology longer term.

At the JP Morgan Healthcare Conference in San Francisco last week, Berry Genomics CEO Daixing Zhou provided an update on the company. Founded in 2010, the company now has around 600 employees and offers three genetic tests.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.